A gene-editing therapy designed to permanently lower cholesterol has shown sustained reductions in patients for at least 12 months after a single treatment. The therapy uses CRISPR technology to edit genes tied to cholesterol regulation, aiming for a one-time fix rather than daily medication.
nature.com
· 2026-09-01
An updated study published in the New England Journal of Medicine shows that a one-time CRISPR-Cas9 gene-editing infusion kept LDL cholesterol and triglycerides roughly 50% lower a full year after treatment in patients who received the highest dose. The follow-up builds on a small November 2025 pilot trial of 15 patients with medication-resistant high cholesterol, testing five dosage levels for safety, with researchers now confirming the effect appears durable rather than temporary.
science.slashdot.org
· 2026-08-29